Gemcitabine: Safety profile and efficacy in non-small cell lung cancer unaffected by age

Aging Clinical and Experimental Research

Volumn 9, Issue 4, 1997, Pages 297-303

  Martin, C ^a   Ardizzoni, A ^b   Rosso, R ^b  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Chemotherapy; Drug therapy; Non small cell lung carcinoma

Indexed keywords

GEMCITABINE;

AGED; AGING; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; DRUG EFFICACY; DRUG TOLERANCE; HUMAN; LUNG NON SMALL CELL CANCER;

EID: 0030855950     PISSN: 03949532     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03341832     Document Type: Article

References (25)

1. Phister J.E., Jue S.E , Cusack B.J.: Problems in the use of anticancer drugs in the elderly. Drugs 37: 551-565, 1989.
2. Walsh S.J., Begg C.B., Carbone P.P.: Cancer chemotherapy in the elderly. Semin. Oncol. 16: 66-75, 1989.
3. Grindey G.G., Boder G.B., Hertel L.H., Kroin J.S., Poore G.A., Rinzel S.M., Todd G.G.: Antitumor activity of 2',2'-difluorodeoxycitidine (LY188011). Proc. Am. Assoc. Cancer Res. 27, 1986, p 296 (A 1775).
4. Chubb S., Heinemann V., Novotny L., Hertel L., Nowak B., Mineishi S., Grindey G B., Plunkett W.: Metabolism and action of 2',2'-difluorodeoxycytidine (dFdC) in human leukemia cell. Proc. Am. Assoc. Cancer Res. 28, 1987, p. 324 (A 1282).
5. Bhalla K., MacLaughlin W., Cole J., Arlin Z., Birkhofer M., Graham G.: Continuously administered 2',2'-difluorodeoxycytidine (dFdC) and deoxycytidine (dCyd): A potentially selective cytotoxic regimen toward human leukemic myeloid progenitors in culture. Proc. Am. Assoc. Cancer Res. 28, 1988, p. 348 (A 1385).
6. Fujita F., Fijita M., Inaba H., Taguchi T.: Antitumor activity of LY188011. a new deoxycytidine analog, against human cancers xenografted into nude mice. Jpn. J. Cancer Chemother. 21: 517-523, 1994.
7. Tanayanagi C., Takauji R., Ueda T.: Action mechanism of difluorodeoxycitidine (dFdC), a new ara-C derivative. Acta Hematol. Jpn. 53: 76, 1990 (A 132).
8. Bouffard D.Y., Momparler L.F., Momparler R.L.: Comparison of antineoplastic activity of cytosine arabinoside and 2',2'-difluorodeoxycytidine on human myelod, T-cell and B-cell leukemic cells. Eur. J. Pharmacol. 183, 161, 1990 (A 32).
9. Plunkett W., Chubb S., Nowak B., Hertel L., Grindey G.B.: Increased cytotoxicity and therapeutic activity of 2',2'-difluorodeoxycytidine over cytosine arabinoside (ara-C) in L1210 leukemia. Proc. Am. Assoc. Cancer Res. 29, 1988, p. 352 (A 1402).
10. Anderson H., Lund B., Bach F., Thatcher N., Walling J., Hansen H.H.: Single-agent activity of weekly gemcitabine in advanced non-small cell lung cancer: A phase II study. J Clin. Oncol. 12: 1821-1826, 1994.
11. Gatzemeier U., Shepherd F.A., Le Chevalier T., Weynants P., Cottier B., Groen H.J., Rosso R., Mattson K., Cortes-Funes H., Tonato M., Burkes R.L., Gottfried M., Voi M.: Activity of gemcitabine in patients with non-small cell lung cancer: A multicenter extended phase II study. Eur. J. Cancer 32: 243-248, 1996.
12. Kaye S.B.: Gemcitabine current status of phase I and II trials. J. Clin. Oncol. 12: 1527-1531, 1994.
13. Abratt R.P., Werner R.B., Falkson G., Goedhals L., Hacking D., Rugg T.: Efficacy and safety of gemcitabine in non-small cell lung cancer: A phase II Study. J. Clin. Oncol. 12: 1535-1540, 1994.
14. Walling J.: Chemotherapy of advanced non-small cell lung cancer. Respir. Med. 88: 649-657, 1994.
15. Carmichael J., Fink U., Russell R.C.G., Spittle M.F., Harris A.L., Spiessi G., Blatter J.: Phase II Study of gemcitabine in patients with advanced pancreas cancer. Br. J. Cancer 73: 101-105, 1996.
16. Casper E.S., Green M.R., Kelsen D.P., Heelan R.T., Brown T.D., Flombaum C.D., Trochanowski B., Tarassoff P.G.: Phase II trial of gemcitabine (2',2'difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest. New Drugs 12: 29-34, 1994.
17. Lund B., Hansen O.P., Theilade K., Hansen M., Neijt J.P.: Phase II study of gemcitabine (2',2'-difluorodeoxycitidine) in previously treated ovarian cancer. J. Natl. Cancer Inst. 86: 1530-1533, 1994.
18. Carmichael J., Possinger K., Phillip P., Beykirch M., Kerr H., Walling J., Harris A.L.: Advanced breast cancer: A Phase II trial with gemcitabine. J. Clin. Oncol. 13: 2731-2736, 1995.
19. Cormier Y., Eisenhauer E., Muldal A., Gregg R., Ayoub J., Gross G., Stewart D., Tarasoff P., Wong D.: Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer. A study of the National Cancer Institute of Canada Clinical Treatment Group. Ann. Oncol. 5: 283-285, 1994.
20. De Mulder P.H.M., Weissbach L., Jakse G., Osieka R., Blatter J.: Gemcitabine: a phase II study in patients with advanced renal cancer. Cancer Chemother. Pharmacol. 37: 491-495, 1996.
21. Mertems W.C., Eisenhauer E.A., Moore M., et al.: Gemcitabine in advanced renal cell carcinoma. A phase II study of the National Cancer Institute of Canada Clinical Trials group. Ann. Oncol. 4: 331-332, 1994.
22. Abbruzzese J.L., Pazdur R., Ajani J., Daugherty K., Tarassoff P., Levin B.: A phase II trial of gemcitabine in patients with advanced colorectal cancer. Proc. Am. Soc. Clin. Oncol. 10: 456, 1991.
23. Christman K., Kelsen D., Saltz L., Tarassoff P.G.: Phase II trial of gemcitabine in patients with advanced gastric cancer. Cancer 73: 5-7, 1994.
24. Poplin P., Thompson B., Whitacre M.: Small cell carcinoma of the lung: influence of age on treatment outcome. Cancer Treat. Rep. 71: 290-296, 1987.
25. Rinaldi M., De Marinis F., Ardizzoni A.: Correlation between age and prognosis in patients with advanced non small cell cancer (NSCLC) treated with cisplatin (CDDP) containing chemotherapy: a retrospective multicenter study. Ann. Oncol. 5 (SuppL 8): 58, 1994.